All In Biotech

Drug Trial Radar · NCT07507760

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

A Phase II, Multicentre, Open Label Clinical Trial Evaluating the Efficacy and Safety of Oral Decitabine Plus Ivosidenib in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia Older Than 60 Years Old and/or Who Are Ineligible for Standard Induction Chemotherapy

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
PETHEMA FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who are older than 18 years old with defined comorbidities that make them not suitable for standard induction therapy. The main objectives of this clinical trial are: * Asses the Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) rates of this treatment. * Determine the incidence and severity of all adverse events (AEs). All participants will receive oral ivosidenib and oral decitabine in treatment cycles of 28 days until disease progression, lack of clinical benefit or the end of the study. Patients who achieve CR/CRi will be elegible to receive allogeneic stem cell transplantation.

Conditions

  • Acute Myeloid Leukemia With Gene Mutations

Interventions

  • Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLETDrug

    Oral Decitabine (Decitabine/Cedazuridine 35 Mg-100 Mg) will be administerd on Days 1-5 of each treatment cycle

  • Ivosidenib Oral TabletDrug

    Ivosidenib 500 mg/orally on Days 1-28 of each treatment cycle

  • HydroxyureaDrug

    0.5-6 gram/day orally during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis

  • CytarabineDrug

    Maximum 1 gram/sqm/day during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis

  • Allogeneic stem cell transplantationProcedure

    Only for those participants achieving CR/CRi

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of CR/CRiTime frame: 3 years

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • ULS Região de Aveiro

    Aveiro, Portugal · Not yet recruiting

  • Hospital Central do Funchal

    Funchal, Portugal · Not yet recruiting

  • Hospital Santa Maria

    Lisbon, Portugal · Not yet recruiting

  • ULS São José

    Lisbon, Portugal · Not yet recruiting

  • Hospital Pedro Hispano

    Porto, Portugal · Not yet recruiting

  • Complejo Hospitalario de Albacete

    Albacete, Spain · Not yet recruiting

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain · Recruiting

  • Hospital Universitario de Burgos

    Burgos, Spain · Recruiting

  • Hospital San Pedro Alcántara

    Cáceres, Spain · Recruiting

  • Complejo Hospitalario Regional Reina Sofía

    Córdoba, Spain · Recruiting

  • Hospital Universitario de Gran Canaria Doctor Negrín

    Las Palmas, Spain · Recruiting

  • Hospital Universitario de Canarias

    Las Palmas de Gran Canaria, Spain · Recruiting

  • Hospital Universitario Lucus Augusti

    Lugo, Spain · Recruiting

  • Fundación Jiménez Díaz

    Madrid, Spain · Not yet recruiting

  • H. 12 de Octubre

    Madrid, Spain · Not yet recruiting

  • Hospital Univeristario Ramón y Cajal

    Madrid, Spain · Not yet recruiting

  • Hospital Virgen de la Victoria

    Málaga, Spain · Recruiting

  • Hospital Universitario Virgen Del Rocío

    Seville, Spain · Recruiting

  • H. Dr. Peset

    Valencia, Spain · Recruiting

  • Hospital Universitari i Politècnic La Fe

    Valencia, Spain · Recruiting

  • Hospital Principe de Asturias

    Alcalá de Henares, Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.